Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine

PR Newswire June 7, 2016

TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016

PR Newswire June 6, 2016

SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering

Accesswire June 2, 2016

TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City

PR Newswire May 27, 2016

TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

PR Newswire April 28, 2016

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

PR Newswire April 21, 2016

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

PR Newswire April 7, 2016

StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.

Marketwired March 17, 2016

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

PR Newswire March 14, 2016

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart - Next-Generation T-Cell Vaccine

PR Newswire February 18, 2016

TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

PR Newswire February 10, 2016

TapImmune, Inc. (OTCQB: TPIV) FDA Grants Fast Track Designation for TPIV 200

Accesswire February 9, 2016

TapImmune to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016

PR Newswire February 8, 2016

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

PR Newswire February 3, 2016

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

PR Newswire January 27, 2016

The Road Ahead - Analyst Notes on OriginClear, TapImmune, Ivanhoe Mines and Alacer Gold

Accesswire January 19, 2016

TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016

PR Newswire January 7, 2016

Biotechs and Tech Lead The Way For 2016

Accesswire December 16, 2015

Five Small Cap Stocks Experiencing Huge Growth Potential

Accesswire December 11, 2015

TapImmune Presents New Data at San Antonio Breast Cancer Symposium Showing Robust Generation of T-Cell Immunity

PR Newswire December 10, 2015